RECENT NEWS - June 14 2007

Drake Holding Corp. Announces Completion of Stock Purchase Agreement with Canopus Corporation.

LOS ANGELES, Jun 14, 2007 (BUSINESS WIRE) -- Drake Holding Corp. (DRKH.PK) consummated a Stock Purchase Agreement with Canopus Corporation, a Belize corporation controlled by Leo Prendergast and Patrick Prendergast, his brother. Pursuant to the Agreement Canopus and the Prendergasts granted to Drake an exclusive License to develop and commercialize products related to novel pharmaceuticals in the areas of antivirals, radiation protection, cancer therapies, camelidae blood products and bio-barcode assay technologies currently being developed by Canopus and its associates. In consideration for the License and rights to certain other properties held by Canopus and its associates, Drake issued 116,677,916 shares of its common stock to Canopus. Immediately upon closing of the transaction the shares issued to Canopus represented approximately 93.5% of the outstanding common shares of Drake. The transaction was approved by the Board of Directors of Drake, who hold approximately 80% of its shares outstanding prior to the transaction.

Upon completion of the transaction, Leo Prendergast, Patrick Prendergast and Len Rothstein were elected to the Board of Directors of Drake. In addition, Patrick Prendergast was elected Chairman and Chief Executive Officer of Drake, Leo Prendergast was elected Chief Operating Officer and Len Rothstein was elected President.

Drake announced that the Board of Directors and shareholders have voted to change the name of the corporation to Canopus BioPharma, Inc and to effectuate a 1 for 15 "reverse split" of the outstanding common shares of Drake. The company anticipates that the name change and 1 for 15 reverse split will be effectuated within twenty days at which time it will announce its new trading symbol and open its website www.canopusbiopharma.com to the public.

In connection with the transaction Drake completed a private placement in which it received commitments for approximately $2,000,000 from a limited group of accredited investors at a price of $2.50 per share, after giving effect to the 1 for 15 reverse split approved by the Board upon consummation of the transaction.

Canopus Corp. is an advanced pharmaceutical research company formed in 1996. Canopus maintains staff in Australia, South Africa, Ireland and the USA.

<-- Go back